Stockscreener 앱 받기
48.70
23.67%
9.315
Jyong Biotech Ltd 주식(MENS)의 최신 뉴스
Jyong Biotech (NASDAQ:MENS) Trading 6.5% HigherWhat's Next? - MarketBeat
Jyong Biotech (NASDAQ:MENS) Shares Down 8%What's Next? - MarketBeat
Jyong Biotech (NASDAQ:MENS) Shares Gap DownTime to Sell? - MarketBeat
Jyong Biotech Wins Innovation Gold Award in Pharmaceutical Category at 2025 Taipei Biotech Awards - GlobeNewswire
First Taiwan-Developed Botanical Drug in FDA Phase III: Jyong Biotech Wins Gold for BPH Treatment - Stock Titan
Jyong Biotech (NASDAQ:MENS) Trading Down 6.1%Here's Why - MarketBeat
MENS Stock Price and Chart — NASDAQ:MENS - TradingView
Jyong Biotech (NASDAQ:MENS) Reaches New 52-Week HighStill a Buy? - MarketBeat
Jyong Biotech (NASDAQ:MENS) Shares Gap UpHere's Why - MarketBeat
Jyong Biotech Chairwoman and CEO Set to Attend as Speaker at 2025 Global Business Forum in Taipei - GlobeNewswire
Taiwan Biotech Leader Joins Global Business Forum: Jyong CEO to Discuss Cross-Border Innovation - Stock Titan
Jyong Biotech (NASDAQ:MENS) Stock Price Down 4.7%Should You Sell? - MarketBeat
Jyong Biotech completes patient enrollment in Phase II trial of MCS-8 - TipRanks
Jyong Biotech Announces Completion of Patient Enrollment of - GlobeNewswire
Jyong Biotech (NASDAQ:MENS) Sets New 12-Month HighHere's Why - MarketBeat
Enrollment goal met in trial of MCS-8 for prostate cancer prevention - Urology Times
Jyong Biotech completes phase II enrollment of 700+ patients for MCS-8 in prostate cancer prevention trial - MarketScreener
Jyong Biotech (MENS) Wraps Up Phase II Enrollment for Cancer Drug Study - GuruFocus
Jyong Biotech Completes Enrollment in Phase 2 Trial of Prostate Cancer Investigational Drug - MarketScreener
700+ Patient Milestone: Jyong Biotech's Prostate Cancer Prevention Drug Advances in Phase II Trial - Stock Titan
Jyong Biotech (NASDAQ:MENS) Trading Up 9.1%What's Next? - MarketBeat
Evaluating Jyong Biotech (NasdaqGM:MENS): What Recent Price Moves Reveal About Its Current Valuation - Yahoo Finance
Examining Jyong Biotech (NasdaqGM:MENS) Valuation Following Recent Share Price Momentum - simplywall.st
Shared decision-making: Clarifying roles in prostate cancer care - Urology Times
Biopharma IPO activity slows, but 2025 returns are surging - BioWorld MedTech
Jyong Biotech (NASDAQ:MENS) Sets New 52-Week HighStill a Buy? - MarketBeat
These Were the 5 Top-Performing Stocks in the Nasdaq Composite in August 2025 - The Motley Fool
Jyong Biotech shares rise 1.06% premarket after being included in a stock market index. - AInvest
Experts discuss the transformative potential of AI for BPH - Urology Times
Jennifer Robles, MD, on future advancements in HoLEP - Urology Times
Jyong Biotech to present clinical data from studies of BOTRESO, MCS-8 - MSN
Jyong Biotech (NASDAQ:MENS) Stock Price Down 6.7%What's Next? - MarketBeat
Jyong Biotech shares rise 1.83% after-hours after participating in the 22nd Urological Association of Asia Congress. - AInvest
Jyong Biotech shares fall 1.93% after-hours following participation in the 22nd Urological Association of Asia Congress. - AInvest
Jyong Biotech Ltd. Participated in the 22nd Urological - GlobeNewswire
Breakthrough: Taiwan's First FDA Phase 3 Botanical Drug BOTRESO Shows Promise in $9.8B BPH Market - Stock Titan
Positive data on BOTRESO and MCS-8 highlight dual advances in prostate health - Urology Times
Jyong Biotech (NASDAQ:MENS) Shares Up 10.5%Here's What Happened - MarketBeat
Biopharma IPO drought continues: chance of rain expected? - BioWorld MedTech
2.83%
자본화:
|
볼륨(24시간):